RAMM Pharma Corp.
RAMM
CNSX
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.05% | -14.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.05% | -14.72% | |||
| Cost of Revenue | 28.71% | -9.88% | |||
| Gross Profit | -99.72% | -31.80% | |||
| SG&A Expenses | -1.15% | -31.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -36.54% | 40.54% | |||
| Total Operating Expenses | 11.13% | -23.58% | |||
| Operating Income | -16.31% | 30.92% | |||
| Income Before Tax | -376.47% | 89.79% | |||
| Income Tax Expenses | -- | 205.10% | |||
| Earnings from Continuing Operations | -160.93% | 79.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -160.93% | 79.72% | |||
| EBIT | -16.31% | 30.92% | |||
| EBITDA | -26.59% | 35.74% | |||
| EPS Basic | -166.67% | 80.00% | |||
| Normalized Basic EPS | 8.70% | 43.90% | |||
| EPS Diluted | -166.67% | 80.00% | |||
| Normalized Diluted EPS | 8.70% | 43.90% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||